Literature DB >> 17638853

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis.

Cem Akin1, Linda M Scott, Can N Kocabas, Nataliya Kushnir-Sukhov, Erica Brittain, Pierre Noel, Dean D Metcalfe.   

Abstract

Idiopathic anaphylaxis remains a perplexing disorder in which existing prophylactic therapy is inadequate. In this prospective study, we sought to determine whether patients with idiopathic anaphylaxis might have evidence for a clonal disorder of mast cells related to mastocytosis and for which novel targeted therapies might be considered. We report 12 patients with "idiopathic" anaphylaxis who did not exhibit either urticaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates observed in systemic mastocytosis. Of these 12 patients, 5 had evidence of 1 or more minor criteria for mastocytosis. C-KIT mutational analysis was positive for the 816D>V activating mutation in 3 of 3 patients in CD25(+) bone marrow cells where the analysis was performed. These results demonstrate the presence of an aberrant mast-cell population carrying clonal markers in a subset of patients diagnosed with "idiopathic" anaphylaxis, who may respond to inhibitors targeting mutated C-KIT. This intramural clinical trial was conducted in 2003 and 2004 and was registered at (http://clinicalcenter.nih.gov) with a study number 03-I-0010. Since the study is now closed, it is no longer available online.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638853      PMCID: PMC1988935          DOI: 10.1182/blood-2006-06-028100

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

Authors:  C Akin; A S Kirshenbaum; T Semere; A S Worobec; L M Scott; D D Metcalfe
Journal:  Exp Hematol       Date:  2000-02       Impact factor: 3.084

Review 2.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

Review 3.  Mastocytosis: current concepts in diagnosis and treatment.

Authors:  L Escribano; C Akin; M Castells; A Orfao; D D Metcalfe
Journal:  Ann Hematol       Date:  2002-11-29       Impact factor: 3.673

4.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

5.  Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.

Authors:  Stefan Florian; Maria-Theresa Krauth; Ingrid Simonitsch-Klupp; Wolfgang R Sperr; Robert Fritsche-Polanz; Karoline Sonneck; Manuela Födinger; Hermine Agis; Alexandra Böhm; Friedrich Wimazal; Hans-Peter Horny; Peter Valent
Journal:  Int Arch Allergy Immunol       Date:  2005-02-17       Impact factor: 2.749

Review 6.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

7.  IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor.

Authors:  Vivian Lam; Janet Kalesnikoff; Corinna W K Lee; Valerie Hernandez-Hansen; Bridget S Wilson; Janet M Oliver; Gerald Krystal
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

8.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

Authors:  Andres C Garcia-Montero; Maria Jara-Acevedo; Cristina Teodosio; Maria Luz Sanchez; Rosa Nunez; Aranzazu Prados; Isabel Aldanondo; Laura Sanchez; Mercedes Dominguez; Luis M Botana; Francisca Sanchez-Jimenez; Karl Sotlar; Julia Almeida; Luis Escribano; Alberto Orfao
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

9.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

10.  Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells.

Authors:  Thomas R Hundley; Alasdair M Gilfillan; Christine Tkaczyk; Marcus V Andrade; Dean D Metcalfe; Michael A Beaven
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

View more
  51 in total

1.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

2.  The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD).

Authors:  Peter Valent; Michel Arock; Cem Akin; Wolfgang R Sperr; Andreas Reiter; Karl Sotlar; Karin Hartmann; Tracy I George; Knut Brockow; Hanneke C Kluin-Nelemans; Jason Gotlib; Dean D Metcalfe; Hans-Peter Horny
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

3.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

4.  Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis.

Authors:  Roberta Zanotti; Patrizia Bonadonna; Massimiliano Bonifacio; Anna Artuso; Donatella Schena; Maurizio Rossini; Omar Perbellini; Sabrina Colarossi; Marco Chilosi; Giovanni Pizzolo
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

Review 5.  Mast Cells and Anaphylaxis.

Authors:  Phil Lieberman; Lene Heise Garvey
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

Review 6.  Pathogenesis, newly recognized etiologies, and management of idiopathic anaphylaxis.

Authors:  James L Kuhlen; Yamini V Virkud
Journal:  Discov Med       Date:  2015-02       Impact factor: 2.970

Review 7.  IgE, mast cells, basophils, and eosinophils.

Authors:  Kelly D Stone; Calman Prussin; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

8.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.

Authors:  Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

Review 9.  Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.

Authors:  Richard Wu; Jonathan J Lyons
Journal:  Curr Allergy Asthma Rep       Date:  2021-05-10       Impact factor: 4.806

Review 10.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.